Evaluation of inflammatory and hematological parameters in patients diagnosed with COVID-19.

INTRODUCTION: This study aims to research the effects of hematological and inflammatory parameters on the prognosis of COVID-19 disease and hospitalization duration. METHODOLOGY: One hundred and eighty-six patients with COVID-19 and a control group consisting of 187 healthy individuals were included in the study. Hematological variables and inflammatory parameters of the patients were recorded on the first and the fifth days of hospitalization. RESULTS: White blood cell count, lymphocyte count, and platelet count were statistically lower, and mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) levels were higher in the patient group compared to the control group. It was observed that the neutrophil count and MPV level were lower, and the platelet count and ferritin level were statistically higher on the fifth day of follow-up compared to the admission day. In contrast, there was a significantly positive correlation between the duration of hospitalization and the fifth day D-dimer (r = 0.546, p < 0.001) and ferritin (r = 0.568, p < 0.001); in addition, there was a negative correlation between the duration of hospitalization and admission day lymphocyte count and the fifth-day lymphocyte count. CONCLUSIONS: Increased levels of ferritin and D-dimer, and decreased count of lymphocytes are among the important factors affecting the duration of hospitalization for COVID-19 patients. Furthermore, we think that neutrophil count and MPV levels are low, and platelet count and ferritin levels are high during the disease. Therefore, these parameters can be used as prognostic indicators of the disease.

COVID-19 ve Aşı

If the rate of immunization with the vaccine is as high as 85-95% in a society, vulnerable populations who are not vaccinated are also protected. The SARS-CoV-2 pandemic, which caused the COVID-19 disease, continues to spread with new mutations despite all individual and national measures taken. Since there is no effective antiviral drug yet, the most important method of fighting the disease is vaccination. The number of vaccines currently in clinical phase studies is 138 (Phase 1: 36, Phase 2: 65, Phase 3: 31). Bunlar sırasıyla komple viron aşıları (canlı attenüe, inaktif), nükleik asit bazlı DNA ve mRNA aşıları, viral vektör aşıları (replikatif ve nonreplikatif) ve rekombinant protein [protein subunit ve virus like particle (VLP) ] aşılarıdır.

COVID-19 and Vaccine

The most important of the ten great public health achievements today is vaccination. Vaccination is an example of social solidarity as well as providing individual protection against disease. If the rate of immunization with the vaccine is as high as 85-95% in a society, vulnerable populations who are not vaccinated are also protected. The SARS-CoV-2 pandemic, which caused the COVID-19 disease, continues to spread with new mutations despite all individual and national measures taken. Since there is no effective antiviral drug yet, the most important method of fighting the disease is vaccination. In a short period of one year, COVID-19 vaccines were developed and started to be used on a global scale with emergency use approval. The discovery of a pandemic vaccine in such a short time is a great achievement for humanity. A total of 408 vaccine studies are currently available, including preclinical studies in 60 countries. The number of vaccines currently in clinical phase studies is 138 (Phase 1: 36, Phase 2: 65, Phase 3: 31). 6 vaccine studies, which are in clinical phase studies, have been terminated. 21 vaccines have been approved for immediate use. Among these vaccine candidates, in addition to the traditional methods, there are also new technologies that have never been licensed before. (English) [ FROM AUTHOR] Günümüzdeki on büyük halk sağlığı başarısından en önemlisi aşılamadır. Aşılama, hastalığa karşı bireysel korumayı sağlamanın yanı sıra aynı zamanda bir toplumsal dayanışma örneğidir. Bir toplumda aşı ile bağışıklama oranı %85-95 gibi yüksek düzeyde ise aşılanmamış kırılgan kesimler de korunmuş olur. COVID-19 hastalığına neden olan SARS-CoV-2 pandemisi, alınan tüm bireysel ve ulusal önlemlere rağmen yeni mutasyonlarla yayılmaya devam etmektedir. Henüz etkili bir antiviral ilaç mevcut olmadığından hastalıkla mücadelenin şimdilik en önemli yöntemi aşılamadır. Bir yıl gibi kısa sürede COVID-19 aşıları geliştirilmiş ve acil kullanım onayı ile küresel ölçekte kullanılmaya başlanmıştır. Bir pandemi aşısının bu kadar kısa sürede bulunmuş olması insanlık adına çok büyük bir başarıdır. Halen 60 ülkede preklinik çalışmalar da dahil olmak üzere toplam 408 aşı çalışması mevcuttur. Klinik faz çalışmaları aşamasında olan aşı sayısı 138'dir (Faz 1: 36, Faz 2: 65, Faz 3: 31). Klinik faz çalışmaları aşamasında olan 6 aşı çalışması sonlandırılmıştır. 21 aşıya acil kullanım onayı verilmiştir. Bu aşı adayları içerisinde geleneksel olarak başvurulan yöntemlere ek olarak daha önce hiç ruhsatlandırılmamış yeni teknolojiler de bulunmaktadır. (Turkish) [ FROM AUTHOR] Copyright of Dicle Medical Journal / Dicle Tip Dergisi is the property of Dicle Tip Dergisi/ Dicle Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)